Multiple pustular lesions in a patient with ulcerative colitis – successfully treated with TNF‐alpha‐inhibitor

2020 ◽  
Author(s):  
Danielle Franziska Boehmer ◽  
Sigrid Möckel ◽  
Kilian Eyerich ◽  
Tilo Biedermann ◽  
Christian Posch
Keyword(s):  
Ulcerative Colitis ◽  
Tnf Alpha

Tu1687 Diminished TNF-Alpha-Mediated Cell Death in Ulcerative Colitis Granulocytes

2013 ◽  
Vol 144 (5) ◽  
pp. S-822
Author(s):  
Mircea T. Chiriac ◽  
Nancy Nalleweg ◽  
Gheorghe Hundorfean ◽  
Markus F. Neurath ◽  
Jonas Mudter
Keyword(s):  
Ulcerative Colitis ◽  
Cell Death ◽  
Tnf Alpha

scholarly journals Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis

2020 ◽  
Vol 55 (2) ◽  
pp. 134-140
Author(s):  
Einat Almon ◽  
Yoseph Shaaltiel ◽  
Wisam Sbeit ◽  
Alex Fich ◽  
Doron Schwartz ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Fusion Protein ◽  
Tnf Alpha

scholarly journals Treatment-refractory ulcerative colitis responsive to indigo naturalis

2021 ◽  
Vol 8 (1) ◽  
pp. e000813
Author(s):  
Julie P Saiki ◽  
Johan OL Andreasson ◽  
Kevin V Grimes ◽  
Lyn R Frumkin ◽  
Elvi Sanjines ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ulcerative Colitis ◽  
Clinical Response ◽  
Tnf Alpha ◽  
Rna Expression ◽  
Murine Colitis ◽  
Indigo Naturalis ◽  
Treatment Refractory ◽  
Colitis Model

BackgroundIndigo naturalis (IN) is an herbal medicine that has been used for ulcerative colitis with an unclear mechanism of action. Indigo and indirubin, its main constituents, are ligands of the aryl hydrocarbon receptor (AhR). We assessed the safety, efficacy, and colon AhR activity of IN given orally to patients with treatment-refractory ulcerative colitis. The role of AhR in IN benefit was further evaluated with an AhR antagonist in a murine colitis model.MethodsThis open-label, dose-escalation study sequentially treated 11 patients with ulcerative colitis with either IN 500 mg/day or 1.5 g/day for 8 weeks, followed by a 4-week non-treatment period. The primary efficacy endpoint was clinical response at week 8, assessed by total Mayo score. Secondary endpoints included clinical remission, Ulcerative Colitis Endoscopic Index of Severity, quality of life, and colon AhR activity measured by cytochrome P450 1A1 (CYP1A1) RNA expression.ResultsTen of 11 (91%) patients, including 8/9 (89%) with moderate-to-severe disease, achieved a clinical response. Among these 10 patients, all had failed treatment with 5-aminosalicylic acid, 8 patients with a tumour necrosis factor (TNF)-alpha inhibitor, and 6 patients with TNF-alpha inhibitor and vedolizumab. Five patients were corticosteroid dependent. Clinical response was observed in all five patients who had been recommended for colectomy. Three patients achieved clinical remission. All patients experienced improved endoscopic severity and quality of life. Four weeks after treatment completion, six patients had worsened partial Mayo scores. Four patients progressed to colectomy after study completion. Colon CYP1A1 RNA expression increased 12 557-fold at week 8 among six patients evaluated. No patient discontinued IN due to an adverse event. Concomitant administration of 3-methoxy-4-nitroflavone, an AhR antagonist, in a murine colitis model abrogated the benefit of IN.ConclusionIN is a potentially effective therapy for patients with treatment-refractory ulcerative colitis. This benefit is likely through AhR activation.Trial registration numberNCT02442960.

Sign in / Sign up

Export Citation Format

Share Document